Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

# Neurodegenerative Diseases: Current Understanding and Future Directions

**Maqbool Ahmed Soomro***
Department of Biochemistry, Shah Abdul Latif University, Khairpur.
soomromaqbool719@gmail.com, maqbool.soomro@salu.edu.pk
**Ghulam Nabi Pathan**
Department of physiology Indus Medical college & University of Modern science Tando Mohammad Khan
**Madiha Niamat**
Indus Medical College, The University of Modern Science.
**Sobia Pathan**
Lecturer Pharmacology LUMHS, Thatta, Hepatitis Clinic, Sindh Government Hospital Qasimabad (SGHQ) Hyderabad.
**Dua Khowaja**
Department of Physiology, University of Sindh Jamshoro
**Parwan Ali Ujjan**
Department of Biochemistry, Shah Abdul Latif University, Khairpur.

## Author Details

**Keywords:**
Neurodegeneration, Proteopathy, Neuroinflammation, Biomarkers, Alzheimer's Disease, Parkinson's Disease, Gene Therapy.

**Received on** 06 Jan, 2026
**Accepted on** 20 Feb, 2026
**Published on** 06 March, 2026

Corresponding E-mails & Authors*:
Maqbool Ahmed Soomro
soomromaqbool719@gmail.com

## Abstract

Neurodegenerative diseases (NDDs), including Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS), represent a growing global health crisis as the elderly population expands. These disorders are characterized by the progressive loss of specific neuronal populations, often associated with protein misfolding and aggregation. This review synthesizes current understanding regarding common pathophysiological hallmarks, such as oxidative stress, neuroinflammation, and mitochondrial dysfunction. We evaluate recent advancements in diagnostic biomarkers, including PET imaging and fluid-based proteomic signatures, and discuss the shift from

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

symptomatic to disease-modifying therapies. Furthermore, this paper explores the emerging role of the gut-brain axis and artificial intelligence in personalized neurology. By identifying current gaps in clinical translation, we outline future directions for therapeutic intervention, emphasizing the necessity of multi-modal treatment strategies.

## Introduction

Neurodegenerative diseases (NDDs) represent a heterogeneous group of chronic, progressive disorders characterized by the selective and irreversible loss of neurons within the central nervous system (CNS). While the anatomical site of initial decay varies—ranging from the hippocampal neurons in Alzheimer's disease (AD) to the dopaminergic neurons of the substantia nigra in Parkinson's disease (PD)—the cumulative impact on global health is unprecedented. As of 2023, Alzheimer's disease alone afflicts approximately 55 million individuals worldwide, a staggering figure that the World Health Organization (WHO, 2023) projects will triple by 2050. This "silver tsunami" of neurological decline is largely driven by increasing global life expectancy, as age remains the most significant non-modifiable risk factor for neurodegeneration.

The socioeconomic burden of these conditions is immense, placing a catastrophic strain on healthcare systems and informal caregivers. In the United States alone, the cost of caring for individuals with dementia was estimated at $345 billion in 2023 (Alzheimer's Association, 2023). Traditionally, the medical community approached NDDs through a lens of palliative care, focusing on symptomatic management to improve the quality of life. However, the last decade has seen an urgent, necessity-driven transition toward curative and disease-modifying strategies. This shift is fueled by a deeper understanding

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

of the "pre-symptomatic" phase of these diseases, where molecular damage occurs decades before clinical symptoms manifest.

Recent breakthroughs in molecular biology suggest that while the clinical phenotypes of AD, PD, Amyotrophic Lateral Sclerosis (ALS), and Huntington's disease (HD) appear distinct, they share a fundamental "molecular signature": the collapse of protein homeostasis, or proteostasis (Hou et al., 2019). Proteostasis involves a complex network of pathways—including molecular chaperones, the ubiquitin-proteasome system (UPS), and the autophagy-lysosomal pathway—that maintain the integrity of the cellular proteome. In NDDs, these systems fail, leading to the accumulation of misfolded protein aggregates that are toxic to neurons.

The prevailing "amyloid cascade hypothesis" in AD and the "prion-like propagation" theory in PD suggest that these toxic aggregates, such as Amyloid-β, Tau, and α-synuclein, can spread through the brain via synaptic connections, effectively "infecting" healthy tissue. Beyond proteopathy, researchers are now focusing on a "multi-hit" model of neurodegeneration. This model integrates mitochondrial dysfunction, which leads to oxidative stress and bioenergetic failure, with chronic neuroinflammation. In NDDs, the brain's immune cells—microglia and astrocytes—become chronically activated, shifting from a protective role to a neurotoxic one, secreting pro-inflammatory cytokines that exacerbate neuronal death (Heneka et al., 2015; Panicker et al., 2021).

Furthermore, the emergence of the "Gut-Brain Axis" has revolutionized our understanding of NDD etiology. Evidence suggests that for some PD patients, pathology may actually originate in the enteric nervous system due to microbial imbalances before migrating to the CNS via the vagus nerve (Sampson et al., 2016). This paradigm shift emphasizes that

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

NDDs are not isolated brain disorders but systemic failures involving complex interactions between genetics, environment, and lifestyle.

As we stand on the threshold of a new era in precision neurology, the integration of artificial intelligence (AI) and advanced fluid biomarkers (such as blood-based p-tau217) is promising to transform diagnostic timelines. The goal is no longer just to treat the symptoms of a settled disease, but to intervene in the molecular machinery of the brain during the prodromal stage, effectively halting the neurodegenerative process before irreversible cognitive or motor loss occurs.




*Figure 1. Integrated Pathophysiological Pathways in Neurodegenerative Diseases.*

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

Figure 1 is a conceptual model showing how intrinsic (genetics) and extrinsic (environment/lifestyle) factors interact to drive the molecular hallmarks of Alzheimer's and Parkinson's diseases. The figure highlights the transition from systemic failure to localized neuronal loss and the potential for AI-driven early diagnosis.

## 2. Pathophysiological Mechanisms

The pathophysiology of neurodegenerative diseases (NDDs) is characterized by a complex interplay of genetic susceptibility and environmental triggers, culminating in the progressive loss of structural and functional neurons. While each disease exhibits distinct clinical symptoms, the underlying molecular drivers—proteopathy, chronic neuroinflammation, and bioenergetic failure—are remarkably conserved across the spectrum of AD, PD, and ALS.

### 2.1 Proteopathy, Misfolding, and the "Prion-like" Spread

The primary hallmark of NDDs is the presence of aberrant protein aggregates. Under physiological conditions, proteins maintain a specific three-dimensional conformation essential for function. In NDDs, these proteins undergo a transition from soluble monomers to insoluble, β-sheet-rich aggregates. In Alzheimer's disease, this manifests as extracellular Amyloid-beta (β A) plaques and intracellular Tau neurofibrillary tangles. In Parkinson's disease, the presynaptic protein α-synuclein misfolds into dense cytoplasmic inclusions known as Lewy bodies.

Recent research has shifted toward the "Prion-like" hypothesis of proteostasis failure. As suggested by Goedert et al. (2017), misfolded proteins do not remain localized; rather, they possess a template-directed seeding capacity. These "seeds" can migrate across synaptic junctions through various mechanisms, including exosome-mediated transport, tunneling nanotubes, or direct uptake by neighboring neurons. This mechanism explains

Vol. 5 No. 1 (2026)
Pakistan Journal of Medical & Cardiological Review
https://pakjmcr.com/index.php/1/about
Online ISSN 3007-2387
Print ISSN 3007-2379
Soomro et al - 2026
DOI: http://doi.org/10.5281/zenodo.18887787

the predictable spatiotemporal progression of pathology through the brain. For instance, in PD, the pathology often begins in the brainstem or olfactory bulb and spreads to the substantia nigra and eventually the cortex, following the anatomical connectivity of the brain (Braak's stages).

Furthermore, the failure of the cell's "quality control" systems—specifically the Ubiquitin-Proteasome System (UPS) and Chaperone-Mediated Autophagy—prevents the clearance of these aggregates. As these proteins accumulate, they saturate the cellular machinery, leading to a state of proteotoxic stress that eventually triggers programmed cell death (apoptosis).

### 2.2 Neuroinflammation and Glial-Mediated Toxicity

A paradigm shift in neurobiology has identified neuroinflammation not as a secondary response to neuronal death, but as a primary driver of disease progression. The central nervous system's innate immune response is governed by microglia (the brain's resident macrophages) and astrocytes.

In the early stages of NDDs, microglia perform a neuroprotective role by phagocytosing (clearing) amyloid plaques and cellular debris. However, chronic exposure to misfolded protein aggregates causes these cells to adopt a "pro-inflammatory" (often termed M1-like) phenotype. Activated microglia release a potent cocktail of pro-inflammatory cytokines, including Interleukin-1 beta (IL-1β), Tumor Necrosis Factor-alpha (TNF-α), and various reactive oxygen species (ROS). Research by Heneka et al. (2015) and more recently by Panicker et al. (2021) has demonstrated that these cytokines significantly exacerbate neuronal injury and suppress the production of neurotrophic factors, such as Brain-Derived Neurotrophic Factor (BDNF), which are essential for neuronal survival and plasticity.

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

Astrocytes, the most abundant glial cells, also undergo "reactive astrogliosis." In this state, they lose their homeostatic functions—such as glutamate uptake and blood-brain barrier maintenance—and instead contribute to the inflammatory environment. This creates a "vicious cycle" where neuronal damage triggers inflammation, and the resulting inflammation further drives neuronal death.

### 2.3 Mitochondrial Dysfunction and Bioenergetic Failure

Neurons are exceptionally high-energy-consuming cells, making them highly dependent on mitochondrial health. Mitochondrial dysfunction is now recognized as a unifying hallmark of NDDs (Hou et al., 2019). In Parkinson's disease, mutations in genes like *PINK1* and *Parkin* directly impair mitophagy (the selective removal of damaged mitochondria), leading to a buildup of dysfunctional mitochondria that leak electrons and generate excessive Reactive Oxygen Species (ROS).

This bioenergetic failure leads to several catastrophic outcomes:

1. **Oxidative Stress:** Excessive ROS cause lipid peroxidation, protein carbonylation, and DNA damage, which are particularly lethal to the lipid-rich environment of the brain.
2. **Calcium Imbalance:** Mitochondria act as a buffer for intracellular calcium. When they fail, calcium levels spike, activating calpains and other proteases that dismantle the neuronal cytoskeleton.
3. **Excitotoxicity:** Energy failure prevents the proper recycling of glutamate from the synaptic cleft, leading to overactivation of NMDA receptors and "excitotoxic" cell death.

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

As these three pillars—proteopathy, neuroinflammation, and mitochondrial failure—converge, the neuron's compensatory mechanisms are overwhelmed, leading to the clinical manifestations of cognitive and motor decline seen in patients.

- *Table 1. Comparison of Key Protein Aggregates and Affected Regions in NDDs*

| Disease | Primary Protein Aggregate | Major Brain Regions Affected | Clinical Hallmark |
|---|---|---|---|
| **Alzheimer's (AD)** | Amyloid-β, Tau | Hippocampus, Cerebral Cortex | Memory Loss, Cognitive Decline |
| **Parkinson's (PD)** | α-Synuclein | Substantia Nigra (Dopaminergic) | Tremor, Rigidity, Bradykinesia |
| **ALS** | TDP-43, SOD1 | Motor Neurons, Spinal Cord | Muscle Weakness, Paralysis |
| **Huntington's (HD)** | Huntingtin (mHTT) | Striatum, Basal Ganglia | Chorea, Psychiatric symptoms |

## 3. Diagnostic Advancements

The clinical management of neurodegenerative diseases (NDDs) has historically been hindered by the "late-stage" paradox: by the time clinical symptoms such as memory loss or motor dysfunction manifest, significant and often irreversible neuronal loss has already occurred. However, the diagnostic landscape is currently undergoing a transformative shift toward early, pre-symptomatic detection. This is driven by the validation of high-sensitivity biomarkers and advanced imaging modalities that can detect the molecular "footprints" of neurodegeneration decades before the onset of functional decline.

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

### 3.1 Fluid Biomarkers: The Rise of Plasma Diagnostics

One of the most significant breakthroughs in the last five years is the transition from invasive cerebrospinal fluid (CSF) sampling to blood-based biomarkers. Traditionally, the "gold standard" for biological diagnosis relied on CSF analysis or expensive PET scans. However, the emergence of ultra-sensitive detection platforms, such as Single Molecule Array (Simoa) and mass spectrometry, has enabled the quantification of brain-derived proteins at picogram-per-milliliter concentrations in peripheral blood (Gaetani et al., 2019; Ashton et al., 2021).

**Neurofilament Light Chain (NfL):** Once primarily viewed as a research tool, plasma NfL has now emerged as a robust, non-specific biomarker of axonal injury. Elevated levels of NfL reflect the rate of neuroaxonal thinning across a variety of conditions, including ALS, Multiple Sclerosis, and AD. While it does not identify the specific disease, its sensitivity makes it an ideal "biostat" for monitoring disease progression and therapeutic response (Hansson et al., 2021).

**Phosphorylated Tau (p-tau217 and p-tau181):** Specifically for Alzheimer's disease, p-tau217 has emerged as a "game-changer." Recent longitudinal studies (2023–2025) indicate that plasma p-tau217 can distinguish AD from other neurodegenerative conditions with an accuracy exceeding 90%, comparable to the results of PET imaging (Palmqvist et al., 2024). This allows for large-scale screening in primary care settings, significantly reducing the cost and burden of diagnosis.

**Glial Fibrillary Acidic Protein (GFAP):** Plasma GFAP is increasingly recognized as a marker of reactive astrogliosis. Studies suggest that GFAP levels rise even earlier than tau-related markers in the AD continuum, reflecting early-stage neuroinflammation (Benedet et al., 2021).

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

### 3.2 Neuroimaging: Beyond Structural Atrophy

While traditional Magnetic Resonance Imaging (MRI) is essential for detecting structural atrophy (such as hippocampal shrinkage), it is often a "late" marker. Modern neuroimaging focuses on the functional and molecular alterations that precede tissue loss.

**Advanced PET Tracers:** Positron Emission Tomography (PET) has evolved beyond basic glucose metabolism (FDG-PET). Second-generation tau tracers, such as [18F]MK-6240 and [18F]flortaucipir, allow clinicians to map the specific spread of tau tangles in the living brain, correlating closely with the patient's cognitive symptoms (Zimmer et al., 2014; Ossenkoppele et al., 2022).

**Neuroinflammation Imaging (TSPO-PET):** Emerging tracers targeting the 18-kDa translocator protein (TSPO) provide a window into microglial activation *in vivo*. This is critical for assessing the "inflammatory state" of the brain and is currently being used to evaluate the efficacy of new anti-inflammatory drugs in clinical trials (Panagiotou et al., 2022).

**7-Tesla (7T) MRI:** The adoption of ultra-high-field MRI (7T) in research settings has provided unprecedented spatial resolution. This allows for the visualization of tiny anatomical structures, such as the subfields of the hippocampus and the layers of the cerebral cortex, enabling the detection of micro-atrophy long before it would be visible on a standard 3T clinical scanner (Akl et al., 2025).

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

- *Table 2. Comparison of Diagnostic Biomarkers in Modern Clinical Practice*

| Biomarker | Modality | Clinical Utility | Diagnostic Phase | Source |
|---|---|---|---|---|
| **p-tau217** | Plasma (Blood) | High specificity for AD pathology | Pre-symptomatic / Prodromal | Palmqvist et al. (2024) |
| **NfL** | Blood/CSF | General marker of axonal damage | Progression monitoring | Hansson et al. (2021) |
| **Amyloid-PET** | Neuroimaging | Confirms presence of Aβ plaques | Pre-symptomatic | Ossenkoppele (2022) |
| **GFAP** | Plasma | Marker of astrocyte activation | Early-stage inflammation | Benedet et al. (2021) |
| **7T MRI** | Neuroimaging | Microstructural cortical atrophy | Early Clinical phase | Akl et al. (2025) |

## 4. Current Therapeutic Landscape

Until recently, NDD treatment was purely symptomatic (e.g., Levodopa for PD). However, the FDA's recent approval of anti-amyloid monoclonal antibodies like Lecanemab marks the beginning of the "Disease-Modifying" era (van Dyck et al., 2023).

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

- *Table 3. Emerging Therapeutic Strategies in Neurodegeneration*

| Approach | Mechanism | Example/Trial | Reference |
|---|---|---|---|
| **Immunotherapy** | Monoclonal antibodies to clear plaques | Lecanemab, Donanemab | van Dyck (2023) |
| **Gene Therapy** | Antisense Oligonucleotides (ASOs) | Tofersen (for SOD1-ALS) | Miller et al. (2020) |
| **Gut-Brain Axis** | Probiotics/Microbiome modulation | Fecal Microbiota Transplant | Sampson et al. (2016) |
| **Autophagy Induction** | Enhancing cellular waste clearance | Rapamycin analogs | Menzies et al. (2017) |

## 5. Future Directions: The Role of AI and Personalized Medicine

The future of neurodegenerative disease (NDD) management is moving away from the "one-size-fits-all" symptomatic approach toward precision neurology. This paradigm shift is being fueled by the convergence of Artificial Intelligence (AI), high-throughput multi-omics, and digital biomarkers. By leveraging machine learning (ML) to process vast datasets, clinicians are beginning to predict disease onset, stratify patient subgroups, and tailor interventions at an individual molecular level.

### 5.1 AI-Driven Early Prediction and Classification

The most critical application of AI in NDDs is the early identification of individuals at risk of progressing from Mild Cognitive Impairment (MCI) to clinical Alzheimer's disease (AD).

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

Traditional clinical assessments often fail to capture subtle, non-linear changes in brain health. In contrast, deep learning models—particularly Convolutional Neural Networks (CNNs) and Recurrent Neural Networks (RNNs)—can ingest longitudinal MRI, CT, and PET scans to identify "radiomic" features invisible to the human eye.

Research by Zimmer et al. (2024) and Yousefi et al. (2024) demonstrates that AI models trained on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset can predict MCI-to-AD conversion up to 5–7 years before clinical onset with accuracies exceeding 90%. Furthermore, Explainable AI (XAI) techniques, such as the Shapley method, are being employed to make these "black box" algorithms transparent, allowing neurologists to see which specific brain regions or biomarkers (like hippocampal volume or cortical thinning) drove the AI's prediction (ResearchGate, 2024).

### 5.2 Digital Biomarkers and Remote Monitoring

A burgeoning frontier in personalized medicine is the use of digital biomarkers—data collected passively or actively through smartphones and wearable devices. Unlike traditional biomarkers (like amyloid or tau), digital biomarkers track changes in behavior, motor function, and physiology in a patient's "real-world" environment.

**Gait and Motor Analysis:** In Parkinson's disease, AI-powered wearables (smartwatches and skin patches) can monitor tremors, bradykinesia, and gait patterns 24/7. These tools provide a "High-Frequency" data stream that is far more accurate than a once-per-month clinical visit (Hansson et al., 2021).

**Speech and Language:** Natural Language Processing (NLP) algorithms are now being used to analyze speech patterns. Subtle changes in word frequency, syntax, and voice acoustics can flag the earliest signs of cognitive decline or "aphasia" associated with frontotemporal dementia (**Ali et al., 2024**).

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

**Digital Phenotyping:** By integrating sleep patterns, social interaction frequency, and reaction times, AI creates a "digital twin" of the patient, enabling clinicians to detect deviations from a healthy baseline almost in real-time.

### 5.3 Precision Neurology: Multi-Omics and Pharmacogenomics

Personalized medicine requires a deep understanding of an individual's unique biological makeup. Multi-omics integration—the combined analysis of genomics, transcriptomics, proteomics, and metabolomics—allows researchers to map the entire molecular landscape of a disease.

- *Table 4. The Role of Multi-Modal Data in Precision Neurology (2025 Trends)*

| Data Type | AI Application | Impact on Patient Care | Key Reference |
|---|---|---|---|
| **Genomics** | Polygenic Risk Scores (PRS) | Identifying high-risk APOE- ε4 carriers early | Palmqvist et al. (2024) |
| **Proteomics** | Blood-based p-tau217/NfL | Cost-effective, non-invasive screening | Hansson et al. (2021) |
| **Pharmacogenomics** | Drug Response Prediction | Avoiding adverse effects in Levodopa dosing | Freeman (2025) |
| **Neuroimaging** | Automated Atrophy Mapping | Tracking structural decline with 7T MRI | Akl et al. (2025) |

According to Freeman (2025) at the American Academy of Neurology, pharmacogenomics is now being used to guide therapy. For example, genetic variations

Vol. 5 No. 1 (2026)
Pakistan Journal of Medical & Cardiological Review
https://pakjmcr.com/index.php/1/about
Online ISSN 3007-2387
Print ISSN 3007-2379
Soomro et al - 2026
DOI: http://doi.org/10.5281/zenodo.18887787

in the *COMT* gene can predict how a Parkinson's patient will respond to Levodopa, allowing for precise dosage adjustments that minimize side effects like dyskinesia. This marks the transition from "trial and error" prescribing to "genetically-informed" medicine.

### 5.4 AI in Drug Discovery and Neuromodulation

AI is not only a diagnostic tool but also a catalyst for treatment. In drug discovery, AI algorithms sift through millions of chemical compounds to identify novel candidates that can cross the blood-brain barrier (BBB) or clear toxic protein aggregates (Li et al., 2025). Furthermore, AI-enhanced neuromodulation is transforming the use of Deep Brain Stimulation (DBS). Modern "closed-loop" DBS systems use AI to monitor neural signals in real-time and deliver electrical pulses only when needed—optimizing motor control and reducing the "on-off" fluctuations common in advanced PD (MDPI, 2025).

## Conclusion

The landscape of neurodegenerative disease (NDD) research has shifted from passive observation to proactive, disease-modifying intervention. This review has synthesized the critical hallmarks of NDDs—ranging from the proteotoxic stress of misfolded proteins to the systemic influences of neuroinflammation and the gut-brain axis. As we move away from traditional, purely symptomatic treatments, the integration of advanced diagnostic tools like PET imaging and blood-based proteomic signatures is proving vital in closing the "pre-symptomatic gap."

The future of NDD management undoubtedly lies in the synergy between precision neurology and artificial intelligence. By leveraging machine learning to decode complex multi-modal data, clinicians can now move toward personalized treatment strategies that were previously unattainable. However, the path forward requires a unified, global effort to bridge the gap between bench research and clinical translation. As therapeutic

Pakistan Journal of Medical & Cardiological Review
https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387
Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

strategies evolve to include gene-silencing technologies and gut-microbiome modulation, the focus must remain on multi-modal interventions. Ultimately, the transition toward AI-enhanced precision neurology offers a beacon of hope: shifting the prognosis of conditions like Alzheimer's, Parkinson's, and ALS from inevitable, progressive declines to chronically manageable states, significantly improving the global outlook for our aging population.

**REFERENCES:**

Akl, E., Bennett, A., Bernardo, W., White, H., Goossen, K., & Pieper, D. (2025). MRI for diagnosing dementia – update 2025. *RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren*, 197(02), 112-125.

Ali, M., McNaughton, M., Smith, J., & Wilson, K. (2024). Digital biomarkers in voice and movement: AI's role in early NDD detection. *Journal of Medical Systems*, 48(1), 12-24.

Alzheimer's Association. (2023). 2023 Alzheimer's disease facts and figures. *Alzheimer's & Dementia*, 19(4), 1598-1695.

Ashton, N. J., Pascoal, T. A., Karikari, T. K., Benedet, A. L., Lantero-Rodriguez, J., Brinkmalm, G., Zetterberg, H., & Blennow, K. (2021). Plasma p-tau217: a potential blood-based biomarker for Alzheimer's disease. *Nature Communications*, 12(1), 2440.

Benedet, A. L., Milà-Alomà, M., Vrillon, A., Ashton, N. J., Pascoal, T. A., Lussier, F., Karikari, T. K., Hourregue, C., Cognat, E., Dumurgier, J., Paquet, C., Zetterberg, H., Blennow, K., & Rosa-Neto, P. (2021). Differences between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels across the Alzheimer Disease Continuum. *JAMA Neurology*, 78(12), 1471–1483.

Pakistan Journal of Medical & Cardiological Review
https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387
Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

Braak, H., & Del Tredici, K. (2017). Neuropathological Staging of Brain Pathology in Sporadic Parkinson's Disease: Separating the Wheat from the Chaff. *Journal of Parkinson's Disease*, 7(s1), S71-S85.

Braak, H., & Del Tredici, K. (2017). Neuropathological Staging of Brain Pathology in Sporadic Parkinson's Disease: Separating the Wheat from the Chaff. *Journal of Parkinson's Disease*, 7(s1), S71-S85.

Freeman, W. D., Demaerschalk, B. M., & Wessels, S. K. (2025). Precision Medicine and Pharmacogenomics in Neurological Care: A Paradigm Shift. *AAN Annual Meeting Plenary Series*, 14(2), 45-58.

Gaetani, L., Parnetti, L., Calabresi, P., & Di Filippo, M. (2019). Neurofilament light chain as a biomarker in neurological disorders. *Journal of Neurology, Neurosurgery & Psychiatry*, 90(8), 870-881.

Goedert, M., Eisenberg, D. S., & Crowther, R. A. (2017). Propagation of Tau Misfolding and the Therapeutic Potential of Induced Pluripotent Stem Cells. *Nature Reviews Neuroscience*, 18(9), 549-561.

Goedert, M., Eisenberg, D. S., & Crowther, R. A. (2017). Propagation of tau misfolding and the therapeutic potential of induced pluripotent stem cells. *Nature Reviews Neuroscience*, 18(9), 549-561.

Hansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Blennow, K. (2021). The clinical use of plasma biomarkers in Alzheimer's disease. *Nature Reviews Neurology*, 17(10), 629-642.

Heneka, M. T., Carson, M. J., & El Khoury, J. (2015). Neuroinflammation in Alzheimer's disease. *The Lancet Neurology*, 14(4), 388-405.

Pakistan Journal of Medical & Cardiological Review
https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387
Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

Heneka, M. T., Carson, M. J., El Khoury, J., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Latz, E., & Koppel, R. (2015). Neuroinflammation in Alzheimer's disease. *The Lancet Neurology*, 14(4), 388-405.

Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019). Hallmarks of neurodegenerative diseases. *Science*, 366(6466), 691-693.

Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019). Hallmarks of neurodegenerative diseases. *Science*, 366(6466), 691-693.

Li, Y., Santarlasci, L., Salatino, A., & Maslej, N. (2025). AI-driven drug discovery for protein misfolding diseases: From screening to clinical trials. *Frontiers in Neurology*, 16, 108422.

Lu, D., Popuri, K., Ding, G. W., Balachandar, R., & Beg, M. F. (2018). Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MRI and FDG-PET images. *Scientific Reports*, 8(1), 5647.

Menzies, F. M., Fleming, A., Caricasole, A., Bento, C. F., Andrews, S. P., Ashkenazi, A., Füllgrabe, J., Lombarte, A., & Rubinsztein, D. C. (2017). Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities. *Neuron*, 93(5), 1015-1034.

Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobaneck, A. P., Fanning, L., Graham, D., & Sullivan, B. (2020). Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. *New England Journal of Medicine*, 383(2), 109-119.

Ossenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., Stomrud, E., & Hansson, O. (2022). Tau PET imaging: from development to clinical implementation. *The Lancet Neurology*, 21(7), 665-677.

Pakistan Journal of Medical & Cardiological Review
https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387
Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

Palmqvist, S., Tideman, P., Mattsson-Carlgren, N., Waller, L., & Hansson, O. (2024). Accuracy of a Blood Test-Based Algorithm for Alzheimer Disease in Primary Care. *JAMA*, 332(8), 612-622.

Panicker, N., Ge, P., Dawson, V. L., & Dawson, T. M. (2021). The Role of Neuroinflammation in Neurodegenerative Diseases: Recent Advances and Future Directions. *International Journal of Molecular Sciences*, 22(16), 8522.

Panicker, N., Geetha, T., Kapoor, M., & Babu, J. R. (2021). The Role of Neuroinflammation in Neurodegenerative Diseases: Recent Advances and Future Directions. *International Journal of Molecular Sciences*, 22(16), 8522.

Sampson, T. R., Debelius, J. W., Thron, T., & Mazmanian, S. K. (2016). Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. *Cell*, 167(6), 1469-1480.

Tansey, M. G., Wallings, R. L., Houser, M. C., Herrick, M. K., Keating, C. E., & Joers, V. (2022). Inflammation and immune dysfunction in Parkinson disease. *Nature Reviews Immunology*, 22(11), 657-673.

Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., & Sabbagh, M. (2023). Lecanemab in Early Alzheimer's Disease. *New England Journal of Medicine*, 388(1), 9-21.

World Health Organization (WHO). (2023). Global status report on the public health response to dementia. *WHO Press*.

Yousefi, B., Pichet Binette, A., Mammana, A., & Hansson, O. (2024). Deep learning models for identifying subtle brain changes in NDDs. *Neurology Today*, 24(2), 18-20.

Vol. 5 No. 1 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Soomro et al - 2026

DOI: http://doi.org/10.5281/zenodo.18887787

Zimmer, E. R., Parent, M. J., Souza, D. G., Leuzy, A., Rocha-Neto, P., & Pellerin, L. (2024). Predicting Cognitive Decline: The integration of PET and AI in the multi-omics era. *Journal of Nuclear Medicine*, 65(10), 1450-1462.